Symptomatic hyperlactatemia: Lessons learned using a point-of-care device in a health care center- and nurse-based antiretroviral program in Rwanda

Clinical Infectious Diseases

Volumn 46, Issue 2, 2008, Pages 320-322

  Van Griensven, Johan ^a,b   Atté, Edi F ^a   Reid, Tony ^b  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b MÉDECINS SANS FRONTIÈRES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

LACTIC ACID;

HEALTH CENTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HYPERLACTATEMIA; LABORATORY APPARATUS, EQUIPMENT AND SUPPLIES; LACTATE BLOOD LEVEL; LACTIC ACIDOSIS; LETTER; NURSE TRAINING; NURSING PRACTICE; POINT OF CARE DEVICE; POINT OF CARE TESTING; PRIORITY JOURNAL; RWANDA;

ACIDOSIS, LACTIC; ACQUIRED IMMUNODEFICIENCY SYNDROME; AMBULATORY CARE FACILITIES; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; HUMANS; LACTIC ACID; POINT-OF-CARE SYSTEMS; RWANDA;

EID: 39449132525     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/524085     Document Type: Letter

References (15)

1. Songa PM, Castelnuovo B, Mugasha EB, Ocama P, Kambugu A. Symptomatic hyperlactatemia associated with nucleoside analogue reverse-transcriptase inhibitor use in HIV-infected patients: a report of 24 cases in a resource-limited setting (Uganda). Clin Infect Dis 2007; 45:514-7.
2. Van Griensven J, De Naeyer L, Mushi T, et al. High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda. Trans Roy Soc Trop Med Hyg 2007; 101:793-8.
3. Lactate.com. Accusport/Accutrend lactate technical information. 3 August 2006. Available at: http://www.lactate.com/ac_techinfo.html. Accessed 10 August 2007.
4. Van Griensven J, Corthouts A, Atté EF, Alonso J. Symptomatic lactic acidemia on stavudine-containing antiretroviral treatment: clinical features of 20 cases and risk factor assessment [abstract 1090]. In: Program and abstracts of the 2007 HIV/AIDS Implementers' Meeting (Kigali, Rwanda). 2007. Available at: http://www.hivimplementers.com/pdf/ OGAC%20Abstract%20Book.pdf. Accessed 10 August 2007.
5. Bolhaar MG, Karstaedt AS. A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, South Africa. Clin Infect Dis 2007; 45:254-60.
6. Falco V, Rodriguez D, Ribera E, et al. Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clin Infect Dis 2002; 34:838-46.
7. Osler M, Stead D, Rebe K, Boulle A, Meintjes G. Severe hyperlactatemia complicating ART with stavudine first-line therapy in South Africa: incidence, risk factors and outcomes [abstract 792]. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections (San Francisco). Alexandria, VA: Foundation for Retrovirology and Human Health, 2007. Available at: http://www.retroconference.org/2006/Abstracts/27629.HTM. Accessed 10 August 2007.
8. Wohl DA, McComsey G, Tebas P, et al. Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin Infect Dis 2006; 43:645-53.
9. Ogedegbe AO, Thomas DL, Diehl AM. Hyperlactataemia syndromes associated with HIV therapy. Lancet Infect Dis 2003; 3:329-37.
10. Bauer AM, Sternfeld T, Horster S, Schunk M, Goebel FD, Bogner JR. Kinetics of lactate metabolism after submaximal ergometric exercise in HIV-infected patients. HIV Medicine 2004; 5:371-6.
11. AIDS Clinical Trials Group. AATCG metabolic complications guides. Available at: http://aactg.s-3.com/metabolic/lactic.pdf. Accessed 10 August 2007.
12. Moyle GJ, Datta D, Mandalia S, Morlese J, Asboe D, Gazzard BG. Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. AIDS 2002; 16:1341-9.
13. Tan D, Walmsley S, Shen S, Raboud J. Mild to moderate symptoms do not correlate with lactate levels in HIV-positive patients on nucleoside reverse transcriptase inhibitors. HIV Clin Trials 2006; 7:107-15.
14. Manfredi R, Motta R, Patrono D, Calza L, Chiodo F, Boni P. Frequency, risk factors and features of hyperlactatemia in a large number of patients undergoing antiretroviral therapy. AIDS 2003; 17:2131-3.
15. Lonergan JT, McComsey G, Fischer RL, et al. Lack of recurrence of hyperlactatemia in HIV-infected patients switched from stavudine to abacavir or zidovudine. J Acquir Immune Defic Syndr 2004; 36:935-42.